Durham Region Health Department

FAX about...

For Health Care Professionals

Infant & High-Risk Children RSV Prevention Program: Order Now

Under Ontario's Infant and High-Risk Children Respiratory Syncytial Virus (RSV) prevention program, there are two products that can be used for the prevention of disease during the RSV season. **Administration of infant RSV products begins October 1 and are available to order now.**

Beyfortus® - Infants and Children

Beyfortus®, a monoclonal antibody (mAb) immunizing agent, **is the preferred method for safeguarding infants** and is publicly funded for the following infants and children:

- Born April 1, 2025, or after **and less than 8 months** of age up to the end of the RSV season.
- Up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, following a discussion with a health care provider, including children with:
    - Chronic lung disease or hemodynamically significant congenital heart disease
    - Severe immunodeficiency or Down syndrome/Trisomy 21
    - Cystic fibrosis with recurrent pulmonary exacerbations requiring hospitalization, deteriorating pulmonary function and/or severe growth delay
    - Neuromuscular disease impairing clearing of respiratory secretions
    - Severe congenital airway anomalies impairing the clearing of respiratory secretions

Infants **born in hospital during the current RSV season** are provided Beyfortus® **before discharge**. Infants born **outside the current RSV season** should receive Beyfortus® through their **health care provider**. Beyfortus® can be administered on the same day or any time before or after routine childhood vaccines, including seasonal (such as influenza) and live vaccines.

… over

Beyfortus® Administration Guidelines for Infants and Children

Category	Weight	Dose	Timing
Infants born during the current RSV season	Less than 5 kg	50 mg in 0.5 mL (100 mg/mL)	Administered from birth
	Greater than or equal to 5 kg	100 mg in 1 mL (100 mg/mL)	Administered from birth
Infants born April 1 or after and less than 8 months of age up to the end of RSV season	Less than 5 kg	50 mg in 0.5 mL (100 mg/mL)	Shortly before the start of the RSV season
	Greater than or equal to 5 kg	100 mg in 1 mL (100 mg/mL)	Shortly before the start of the RSV season
Children over 8 months and up to 24 months of age and at continued high-risk from RSV infection during second RSV season	N/A	200 mg (two 1 mL injections of 100 mg/mL)*	Shortly before or during RSV season
*If a child weighs less than 10 kg entering their second RSV season, consideration can be given to administering a single dose of 100 mg at the clinical discretion of the provider.			

Abrysvo™ - Pregnant Individuals

The Abrysvo™ vaccine is administered to pregnant individuals (32 to 36 weeks gestation) who will deliver during the RSV season, in consultation with a health care provider. Abrysvo™ may be given on the same day as tetanus, diphtheria, acellular pertussis, COVID-19, and influenza vaccines.

Administration of both Abrysvo™ to the pregnant individual AND Beyfortus® to the infant is NOT recommended except under specific circumstances:

- Infants born less than 14 days after administration of Abrysvo™ **OR**
- Infants who meet the medical criteria for increased risk of severe RSV disease:
  - All premature infants (i.e., <37 weeks gestation)
  - Infants who meet any of the above high-risk criteria

Ordering

Order Beyfortus® or Abrysvo™ now, using the **New Seasonal Respiratory Vaccines Online Order Form** (durham.ca/hcp > Forms > Order).

This year, **vaccine order notifications will be sent by email instead of by phone**. Please note that orders will be ready for **pick-up within 7–10 business days**, and you will receive an email once your order is available. **To prevent delays during pick up, please ensure your vaccine cooler is prepared according to vaccine storage and handling guidelines.**

For further information, including eligibility and Health Care Provider Fact Sheets, visit durham.ca/hcp (Respiratory illnesses > Respiratory Syncytial Virus (RSV) > Resources).

September 25, 2025